Trial reportExperimental and clinical psychopharmacology2026
Glitches to growth: Lessons learned from developing and testing an augmented reality smartphone app for substance use treatment.
Trial report in Experimental and clinical psychopharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06088498 (Augmented Reality as an Adjunct to Quitline Counseling for Smoking Cessation), which is not on this map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Augmented Reality as an Adjunct to Quitline Counseling for Smoking Cessation
Who cites it
1 citing paper in PubMed.
- Mobile App-Based Smoking Cessation in Hispanic or Latino Adults: Culturally Tailored Spanish-Language Formative App Development Study.JMIR formative research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
Augmented reality (AR) is an advanced technology that has emerged as a helpful tool in mobile health interventions for substance use treatment. By superimposing virtual drug-related cues in one's real-world environment, AR could expand the delivery of extinction-based cue exposure therapies while mitigating costs and risks. Previous findings from our team show AR smoking cues elicit cravings like in vivo cues, with evidence of extinction after repeated AR exposure trials. Based on these findings, we developed an AR smoking cessation smartphone app to test as an adjuvant to a state tobacco quitline in an ongoing large-scale randomized controlled trial (NCT06088498). This article describes AR technology and its theoretical relevance to cue exposure therapies, as well as challenges related to app development, trial enrollment, and app engagement. Although some challenges and recommendations unique to AR are discussed (e.g., development of smoking-related AR images), most are relevant to the broader application of other advanced mobile health technologies. Examples include finding and collaborating with industry partners, such as app developers, with sufficient expertise in the relevant technology and in research; potential for selection bias based on smartphone capabilities and participants' technological abilities and affinities; explaining the novel treatment rationale within the app; and maximizing app engagement. Where relevant, these points will be illustrated with data collected during the randomized controlled trial. Recommendations offered may have utility for investigators and clinicians interested in AR and other advanced technologies (e.g., virtual reality, geo-mapping, wearables) to improve the reach and efficacy of treatments for substance use disorders. (PsycInfo Database Record (c) 2026 APA, all rights reserved).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.